Staging and Prognostic Factors
The American Joint Committee on Cancer staging system for cutaneous melanoma was revised in 2002 based on an analysis of prognostic factors in 17,600 cases. (The 7th Edition of the AJCC Cancer Staging Manual will be published in August 2009.) Melanomas without regional lymphatic spread are designated as Stage I or II. Staging of node-negative melanomas is based on the thickness of the primary lesion; ulceration (absence of an intact epidermal layer overlying the melanoma); and, for thin melanomas (< 1 mm), the anatomic depth of invasion (see Tables 2 and 3).
Stage III is defined by involvement of regionallymphaticsorlymph nodes. The tumor burden in the lymph nodes ishighly predictive of outcome. It is represented by the number of nodes involved, and whether involvement is microscopic (clinically unapparent prior to surgery), or macroscopic (clinically apparent).
Stage IV melanoma represents distant metastatic spread, and is stratified according to sites of involvement and lactate dehydrogenase (LDH) level.Though the median survival time is less than 1 year, there is a meaningful proportion of long-term survivors (15.7%) among patients with metastases limited to skin and subcutaneous tissues (M1a). Based on these T, N, and M criteria, patients can be grouped according to prognosis(see Tables 2 and 3). Regardless of stage,age and male gender are adverse prognostic factors, and melanomas arising on the head and neck are associated with a worse prognosis than those at other sites.
Treatment of Melanoma
Wide local excision is the treatment for primary melanomas. Surgical margins are determined based on the thickness of the lesions, with margin guidelines supported by several large, randomized clinical trials and recommended by the National Comprehensive Cancer Network (NCCN). Patient outcomes demonstrate that for thin, primary melanomas (of 1.0 mm or less), a 1-cm margin is adequate. For lesions thicker than 1 mm, 2-cm margins are recommended (see Table 4).Margins may be modified to accommodate individual anatomic or cosmetic considerations.Evaluation for regional nodal involvement is a critical part of staging, since nodalstatus is the single most important prognostic factor in melanoma.
For patients with no clinical evidence of nodal involvement, elective lymph node dissection does not improve survival and hasbeen superseded by sentinel lymph node assessment.Sentinel lymph nodemapping involves injection of aradiotracer or dye around the primary melanoma.The tracer istracked to the “sentinel” node or nodes, which can be excised through a small incision.Sentinel node biopsy is areliable means of identifying melanoma in regional lymph nodes.
If the sentinel nodes do not contain evidence of metastatic melanoma, then the remaining lymph nodes in the basin are also highly likely to be free of disease and thus further nodal dissection is spared.Completion (or therapeutic) nodal dissection is advised when a positive sentinel node has been identified.Sentinel node evaluationshould be considered for patients with melanomas > 1 mm, or in the case of lesions less than 1 mm, if there are adversepathologic factors such as ulcerationormitoses.
The definition of high riskisambiguous but generally refers to patients with a predicted likelihood of distant failure of more than 50% after stage-appropriate surgery. Prognosis for patients with cutaneous melanoma is dependent on the number of involved regional nodes and the thickness of the primary tumor. Patients with pathologic or clinical evidence of regional nodal metastases and those with thick primary lesions (T4) have been demonstrated to be at high risk of disease recurrence. Once palpable nodal disease develops, the ability to provide effective local/regional control and long-term survival is diminished.
Standard treatment typically includes resection of the primary tumor with appropriate margins, and in the case of patients with palpable lymphadenopathy, therapeutic dissection of the regional nodal basin.Imagingstudies such as PET or CT scansare not indicated for asymptomatic patients since detection of distant metastases is uncommon.
High-dose interferon (HDI) alfa-2b (Intron A) is the only US Food and Drug Administration (FDA)-approved adjuvant therapy for resected, high-risk melanoma, and it remains the best-evaluated and most effective available option aimed at reducing the risk of relapse in patients with high-risk melanoma. Its efficacy remains controversial, however. The role of interferon alfa-2b(Drug information on interferon alfa-2b) has been established by three large clinical trials conducted in the US, all demonstrating an improvement in relapse-free survival (RFS), and two showing an improvement in overall survival (OS).
HDI seems to reduce the risk of relapse in only a subgroup of patients,[3,21] and because the medication is expensive and toxicity associated with therapy can be significant, acceptance of the treatment has been limited. Nevertheless, the toxicities appear justified by the potential benefit. Kirkwood et al.  recognize that treatment is indeed associated with significant toxicity, but they argue that the majority of patients can tolerate the 1 year of therapy required if clinicians provide education about the treatment and its anticipated toxicities in conjunction with appropriate dose modifications and available supportive care.
No treatment has been demonstrated to improve median survival in metastatic melanoma, and response rates to systemic therapies are low. Despite these grim statistics, there are occasional long-term survivors, including up to 15% of patients with M1a metastases. A small and highly select group of patients with advanced melanoma may achieve prolonged freedom from relapse after surgical resection of metastases.
Chemotherapy. Melanoma is relatively refractory to standard cytotoxic agents. Objective response rates to single-agent chemotherapy are in the range of 10%–23%, and are typically of brief duration. Response rates to combination chemotherapy are somewhat higher, but toxicity is increased with the use of multiple agents and no survival advantage has been demonstrated. Dacarbazine(Drug information on dacarbazine) (DTIC) has been considered a “standard” treatment, yet responses are observed in less than 20% of patients. In a randomized trial, DTIC was compared with the oral methylating agent temozolomide(Drug information on temozolomide) (Temodar) and response rates were similar (13.5% with temozolomide and 12.1% with DTIC). Progression-free survival was slightly prolonged in the temozolomide arm (1.9 vs 1.5 months), but there was no statistical difference in survival (7.7 and 6.4 months with temozolomide vs DTIC, respectively).
Immunotherapy. Interleukin-2 (IL-2) is a central regulator of the cellular immune response, inducing activation and proliferation of T cells and NK cells. In vitro, it stimulates development of lymphokine- activated killer (LAK) cells, which can lyse autologous tumor cells. IL-2 treatment has been evaluated extensively in patients with metastatic melanoma and was approved by the FDA in 1998. Initial studies with HD bolus IL-2 demonstrated overall response rates in 15%–20% of patients, with 4%–6% of patients achieving durable responses. Patients with metastases limited to skin and subcutaneous sites appear most likely to benefit.
Long-term follow-up of patients treated in early HD IL-2 trials confirms that IL-2 produces a significant clinical benefit for a minority of patients. The substantial toxicity associated with the agent, including a capillary leak syndrome, hemodynamic instability, and a high risk of infection make its use restricted to patients with excellent organ function and performance status, and to experienced clinicians in institutions capable of providing a comprehensive and intensive level of care. IL-2 has been evaluated in various contexts: with adoptive cellular immunotherapy using autologous LAK cells or tumor-infiltrating lymphocytes, with other cytokines, and with chemotherapy agents and vaccines. To date, none of these approaches has demonstrated clear superiority compared with IL-2 given as a single agent.
Recent investigations in immunotherapy have focused on overcoming barriers to generating a sustained and effective antitumor immune response. Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) is expressed on activated T cells. When CTLA4 is engaged by its ligands on antigen-presenting cells, it sends a negative signal to turn off the T cell. Ipilimumab, a monoclonal antibody that binds to CTLA4 and blocks it from binding to the antigen-presenting cell, is currently in clinical trials, and has been demonstrated to enhance antitumor immune responses by removing the negative immune signal. Complete responses and sustained partial responses have been reported in up to 13% of patients with metastatic melanoma treated with these agents, but serious autoimmune toxicity, including enterocolitis and hyphophysitis, has also been observed.
As with HDI in the adjuvant setting, there appears to be a correlation between autoimmune phenomena, such as colitis, diarrhea, vitiligo, dermatitis, pruritis, thyroiditis, and panhypopituitarism and the efficacy of treatment. Colitis induced by these agents responds to treatment with corticosteroids and other medications, but early recognition of symptoms and institution of treatment is essential, making patient education crucial. The importance and rationale of early reporting of symptoms, particularly loose stools, must be stressed to patients.
Targeted Therapy for Melanoma
Over the past several years, important advances in oncology have resulted from a detailed understanding of the molecular biology of cancer and the subsequent development of targeted drugs that inhibit key pathways on which the growth and survival of a particular cancer depend. Research has begun to uncover the genetic abnormalities underlying dysregulated growth, resistance to apoptosis, invasion, and metastasis in melanoma. Substantial molecular heterogeneity has been discovered among melanomas, but a number of mutations occur with high frequency and appear to be critical for survival and growth. Activating mutations in the mitogen-activated protein (MAP) kinase signal transduction pathway are found in the majority of melanomas, most frequently involving the B-raf and N-ras genes.
Inhibitors of B-raf and MEK. Approximately 50%–70% of melanomas harbor mutations in the signaling protein B-raf. In vitro and in vivo data suggest that mutated B-raf plays a key role in the pathogenesis of melanoma. The oral kinase inhibitor sorafenib(Drug information on sorafenib) (Nexavar), approved for treatment of advanced renal cell carcinoma and unresectable hepatocellular carcinoma, was found to be ineffective in phase III trials in melanoma. However, more potent and selective B-raf inhibitors are currently being evaluated in early-phase trials. Preclinical studies have suggested that cancers with B-raf mutations are exquisitely sensitive to inhibition of MAP extracellular signal–regulated kinase (MEK), the signaling molecule immediately downstream from B-raf in the MAP kinase cascade. Specific MEK inhibitors are therefore also of great interest and are currently in phase I and II trials.
C-kit in melanoma. A small subgroup of melanomas harbor mutations or amplification in the gene encoding the receptor tyrosine kinase c-kit. These include some melanomas arising on mucosal surfaces (anorectal, vaginal, sinonasal, etc.), as well as acral melanomas (those arising on the hands and feet) and some melanomas arising in patients with a history of chronic sun-damaged skin. These melanomas have generated intense interest because of the availability of drugs that potently inhibit c-kit, including imatinib (Gleevec), dasatinib(Drug information on dasatinib) (Sprycel), and nilotinib(Drug information on nilotinib) (Tasigna). These agents are highly effective in gastrointestinal stromal tumors that are also characterized by c-kit mutations. Preliminary reports suggest that these agents can induce dramatic and sustained responses in patients with melanomas harboring c-kit mutations, the first instance of effective targeted therapy for melanoma. Several clinical trials are ongoing.
The role of the oncology nurse in the care of patients with melanoma is essential. Owing to the lack of effective systemic treatments, patients frequently are treated in large academic referral centers, and therefore many nurses will have limited yet important interactions with melanoma patients. Nurses can help to educate patients about an often complicated disease, offering psychological support and guidance as well as reiterating goals of care and the rationale for specific treatment recommendations.
Oncology nurses who care for patients with melanoma must understand the unique toxicity profiles of many of the novel therapies and anticipate their side effects. Patient education and counseling regarding prompt reporting of developing symptoms is crucial to management. For other agents, such as IL-2, which has a tremendous toxicity profile, nurses require specialty training and are a cornerstone in the delivery of this therapy.
Regardless of experience with patients who have melanoma, oncology nurses must individualize support and counsel according to the potential trajectory of the patient’s melanoma experience. Of critical importance is the nursing role in primary prevention strategies such as early detection, use and proper application of sunscreening products, skin self-examination, and access to care for a suspicious lesion.
Financial Disclosure: Krista M. Rubin serves on a speakers bureau for Schering Plough Oncology and Novartis and on an advisory board of Schering Plough Oncology. Donald P. Lawrence serves on an advisory board of Schering Plough Oncology.